Myeloid Beta-Arrestin 2 Depletion Alleviates Metabolic Dysfunction-Associated Steatohepatitis through Metabolic Reprogramming of Macrophages

Medicine, Hepatobiliary System, Gastroenterology, Life Sciences, Cell Biology, Biochemistry, Immunology,
Myeloid Beta-Arrestin 2   Metabolic Reprogramming   Macrophages   Steatohepatitis   Inflammation  

The Loss of β-arrestin 2 in Hepatic Macrophages Alleviates Metabolic Dysfunction-associated Steatohepatitis — Through Metabolic Reprogramming of Macrophages Background and Motivation Metabolic dysfunction-associated fatty liver disease (MASLD) is a globally prevalent health issue, affecting approximately 25% of the population. This disease includes...

Needs Assessment for the Creation of a Platform Trial Network in Metabolic-Dysfunction Associated Steatohepatitis

Medicine, Hepatobiliary System, Endocrinology,
Metabolic Dysfunction   Steatohepatitis   Clinical Research Network   Platform Trial   Drug Development  

Needs Assessment for Establishing a Platform Trial Network: A Case Study on Metabolic Dysfunction-Associated Steatohepatitis (MASH) Academic Background The public health issue posed by Metabolic Dysfunction-Associated Steatohepatitis (MASH) is becoming increasingly severe. MASH is a condition caused by fat accumulation, inflammation, and cell damag...

Hepatic Danger Signaling Triggers TREM2+ Macrophage Induction and Drives Steatohepatitis via MS4A7-Dependent Inflammasome Activation

Medicine, Hepatobiliary System, Basic Medical Sciences, Life Sciences, Cell Biology, Immunology,
Liver   TREM2+ Macrophages   MS4A7   Inflammasome   Steatohepatitis   Immune Response   Metabolic Disease  

Liver Danger Signal Triggers TREM2+ Macrophage-Mediated MS4A7-Dependent Inflammasome Activation Driving Steatohepatitis Background and Research Motivation In recent years, with the increasing incidence of metabolic dysfunction-associated steatohepatitis (MASH), its pathological mechanisms have garnered significant attention. MASH, formerly known as...